Source: https://www.taylorenglish.com/people-siegfried-jw-ruppert-phd.html
Timestamp: 2019-04-20 06:31:05+00:00

Document:
Taylor English is an innovative law firm that puts clients first. Being at Taylor English allows me to work with biotech, institutional, and start-up clients and respond efficiently to their complex intellectual property matters – all while providing my services in a cost-effective and value-driven manner.
Siegfried J.W. Ruppert, Ph.D., is a Partner in Taylor English’s Intellectual Property Practice Group. Dr. Ruppert focuses his practice on representing U.S. and foreign clients, including start-up companies, in matters regarding patent prosecution, patent litigation, patent interference, patent infringement analysis and opinion work. Dr. Ruppert has utilized his background as a scientist at Genentech, Inc. and his Ph.D. in Biological Sciences to represent clients in an expansive range of patent subject matters related to biotechnology, life sciences and devices.
As Special Counsel with Duane Morris LLP, and as IP Attorney with Townsend and Townsend and Crew LLP, Dr. Ruppert efficiently managed clients’ U.S. and international patent portfolios, productively worked with clients’ in-house counsel, and effectively represented corporate and start-up companies in the areas of pharmaceuticals, biotechnology, diagnostics, medical devices, and UV devices. He also counseled clients in opinion matters (freedom-to-operate, infringement, patentability and patent validity). Recently, Dr. Ruppert published several articles on biosimilars. He frequently speaks on diverse subject matters ranging from biosimilars to patent eligibility both in the U.S. and abroad.
Prior to his legal career, Dr. Ruppert worked as a Postdoctoral Fellow at the Ruprecht-Karls University of Heidelberg, Germany, and at the University of California, at Berkeley, co-authored approximately 40 scientific articles in peer-reviewed journals, and also became an inventor on a number of U.S. patents.
Dr. Ruppert obtained his law degree from the University of California, Hastings College of the Law, and graduated from the Ruprecht-Karls University of Heidelberg in Heidelberg Germany with a Ph.D. in Biological Sciences.
Pertaining to UV devices, systems comprising UV devices and methods of using UV devices for sterilization, on behalf of a U.S. start-up company.
Pertaining to ultraviolet (UV) sterilization of rooms, space or defined environments, on behalf of a U.S. start-up company.
Pertaining to modified cytosine polynucleotide oligomers and methods of using same, on behalf of a U.S. company.
Pertaining to modified thymine polynucleotide oligomers and methods of using same, on behalf of a U.S. company.
Pertaining to methods of UV sterilization, on behalf of a U.S. start-up company.
Pertaining to the treatment of HIV-1 Infection and AIDS, on behalf of a U.S. research institute.
Pertaining to methods forming nucleic acid complexes comprising HIV-1 nucleic acids, on behalf of the National Institutes of Health.
Pertaining to methods of making and administering quinoline derivatives as anti-cancer agents, on behalf of a Chinese university.
Pertaining to compositions comprising HIV-1 nucleic acids, on behalf of the National Institutes of Health.
Pertaining to multilayer composite filters and methods of making same, on behalf of a Chinese company.
Pertaining to methods for non-invasive diabetic retinopathy detection and monitoring, on behalf of a Chinese university.
Pertaining to automated testing for palpating diabetic foot patient, on behalf of a Chinese university.
Pertaining to therapeutic compositions for intranasal administration of Zolpidem, on behalf of a Chinese biotech/pharma company.
Pertaining to methods of mass production of tetrakis(p-nitrophenyl)-porphyrins, on behalf of a Chinese university.
Pertaining to first generation HIV-1 diagnostic methods, on behalf of the National Institutes of Health.
Pertaining to devices for preparation of cells, on behalf of a U.S. start-up company.
Pertaining to biomarkers of gastric cancer and uses thereof, on behalf of a Chinese university.
Pertaining to removal of endotoxin using amphiphilic core-shell nanosorbents, on behalf of a Chinese university.
Pertaining to methods and apparatuses for reducing residual torque and neps in singles ring yarns, on behalf of a Chinese university.
Pertaining to multilayer nanofiber filters, on behalf of a Chinese university.
Pertaining to influenza prevention and treatment compositions, on behalf of a Chinese company.
Pertaining to a conditioning agent and methods for making hair having a shape memory effect, on behalf of a Chinese university.
Pertaining to water-soluble polymer-based canthararimides as potentially selective anti-tumor agents, on behalf of a Chinese university.
Pertaining to methods for treating Lentivirus infections, on behalf of a U.S. research institute.
Pertaining to methods and systems for the detection of chloramphenicol, on behalf of a Chinese university.
Pertaining to treatment and prevention of hyperproliferative conditions in humans and antisense oligonucleotide inhibition of human replication-initiation proteins, on behalf of a Chinese university.
Pertaining to monoclonal antibodies to HIV-1 and methods of using same, on behalf of the National Institutes of Health.
Pertaining to the cloning and expression of HTLV-III (HIV-1) DNA, on behalf of the National Institutes of Health.
Pertaining to a method for purifying proteins, on behalf of a U.S. biotechnology company.
Pertaining to sensitizing cells for apoptosis by selectively blocking cytokines, on behalf of a German biotechnology company.
Pertaining to noninvasive methods for detecting non-host DNA in a host using epigenetic differences between the host and non-host DNA, on behalf of a Chinese university.
Novartis Vaccines And Diagnostics, Inc. v. United States Department Of Health And Human Service.
Supported counsel for the United States Department Of Health And Human Services in litigation against Novartis involving first-generation HIV-1 hybridization assays. Case No. 07-02138 (RWR) (District of Columbia).
The United States of America v. Institut Pasteur, et al.
Supported counsel for The United States of America in litigation against Institut Pasteur involving first-generation HIV-1 hybridization assays. Judgment by Consent in favor of client, The United States Of America. Case No. 08-00161 (RWR) (District of Columbia).
Aspex Eyewear Inc. v. Zenni Optical, LLC.
Assisted in a patent appeal in the Federal Circuit obtaining an affirmation of a trial court victory for client against collaterally estopped infringement claims regarding magnetically attached auxiliary frames for eyeglasses. Case No. 2012-1318 (Fed. Cir. 2013).
Aspex Eyewear, Inc. and Contour Optik, Inc. v. Zenni Optical, LLC.
Patent Infringement: Counsel for Zenni Optical, LLC in a patent infringement action involving magnetic eyewear. Obtained summary judgment in favor of internet retailer Zenni Optical, LLC against claims that it infringed patents for magnetic eyeglass frames. Case No. 0:09-cv-61468-WJZ (S.D. Fla.).
Ormco Corporation v. Align Technology, Inc.
Supporting Counsel for Align Technology, Inc. in a patent infringement action involving four patents regarding methods of straightening teeth. Obtained win for Align Technology, Inc. on motion for summary judgment of non-infringement. Case No. 03-cv-00016 (Central District of California).
Mophie, Inc. v. Incase Designs Corp.
Counsel for Mophie, Inc. Prosecuted Mophie, Inc.’s patent application involving battery packs for mobile devices and succeeded in including all claims and all issued patents of opposing party in interference. Patent Interference No. 105,946 (USPTO).
The J. David Gladstone Institutes v. Oregon Health And Science University.
Supported The J. David Gladstone Institutes in obtaining favorable settlement in a patent interference involving HIV-1 technology. Patent Interference No. 105,686 (USPTO).
University of California v. Alza Corporation.
Obtained judgment of priority for the University of California in an interference involving targeted therapeutic liposomes. Patent Interference No. 105,332 (USPTO).
Counsel for the National Institutes of Health in a patent interference against Novartis/Chiron involving first-generation HIV-1 hybridization assays. Obtained judgment of priority for client. Confirmed on appeal. Patent Interference No. 105,291 (USPTO).
Counsel for the National Institutes of Health in a patent interference against Institut Pasteur involving first-generation HIV-1 hybridization assay (hybridization assays). Obtained judgment of priority for client after conclusion of appeal in district court. Patent Interference No. 105,290 (USPTO).
“Rb interacts with TAFII250/TFIID through multiple domains distinct from E2F and viral oncoprotein binding regions,” Co-Author, (1997) Oncogene 15, 385-392.
“Apo-2 ligand activates apoptosis in stimulated peripheral blood T cells,” Co-Author, (1996) Current Biology 6, 750-752.
“Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family,” Co-Author, (1996) J. Biol. Chem 271, 12687-12690.
“TAFII250 is a bipartite protein kinase that phosphorylates the basal transcription factor RAP74,” Co-Author, (1996) Cell 84, 781-790.
“Human TAFII250 interacts with RAP74: implications for RNA polymerase II initiation,” Co-Author, (1995) Genes & Dev. 9, 2747-2755.
“The retinoblastoma-susceptibility gene product binds directly to the human TATA-binding protein-associated factor TAFII250,” Co-Author, (1995) Proc. Natl. Acad. Sci. USA 92, 3115-3119.
“Multiple regions of TBP participate in the response to transcriptional activators in vivo,” Co-Author, (1994) Genes & Dev. 8, 2756-2769.
“Rescue of mice homozygous for lethal albino deletions: Implications for an animal model for human liver disease tyrosinaemia type 1,” Co-Author, (1993) Genes & Dev. 7 (12a), 2285-2297.
“Cloning and expression of Drosophila TAFII60 and human TAFII70 reveals conserved interactions with other subunits of TFIID,” Co-Author, (1993) EMBO Journal 12 (13), 5303-5309.
“Cloning and expression of human TAFII250: a TBP-associated factor implicated in cell-cycle regulation,” Co-Author, (1993) Nature 362, 175-179.
“Molecular characterization of the mouse tyrosinase gene: Pigment cell-specific expression in transgenic mice,” Co-Author, (1992) Pigment Cell Research 5, 295-29.
“Deficiency of an enzyme of tyrosine metabolism underlies altered gene expression in newborn liver of lethal albino mice,” Co-Author, (1992) Genes & Dev. 6, 1430-1443.
“The mouse CREB (cAMP responsive element binding protein) gene: structure, promoter analysis, and chromosomal localization,” Co-Author, (1992) Genomics 13 (4), 974-982.
“Multiple mRNA isoforms of the transcription activator protein CREB: generation by alternative splicing and specific expression in spermatocytes,” Co-Author, (1992) EMBO Journal 11, 1503-1512.
“Tyrosinase as a marker for transgenic mice,” Co-Author, (1991) Nucleic Acids Res. 19, 958.
“Rescue of the albino phenotype by introduction of a functional tyrosinase gene into mice,” Co-Author, (1990) EMBO Journal 9, 2819-2826.
“New type of POU domain in germ line-specific protein Oct-4,” Co-Author, (1990) Nature 344, 435-439.
“Two genetically defined trans-acting loci coordinately regulate overlapping sets of liver-specific genes,” Co-Author, (1990) Cell 61, 895-904.
“A cloned octamer transcription factor stimulates transcription from lymphoid-specific promoters in non-B cells,” Co-Author (1988) Nature 336, 544-551.
“Multiple transcripts of the mouse tyrosinase gene are generated by alternative splicing,” Co-Author, (1988) EMBO Journal 9, 2715-2722.
“Genomic footprinting reveals cell type-specific DNA binding of ubiquitous factors,” Co-Author, (1987) Cell 51, 435-443.
“Recent gene conversion involving bovine vasopressin and oxytocin precursor genes suggested by nucleotide sequence,” Co-Author, (1984) Nature 308, 554-557.
“Deduced amino acid sequence from the bovine oxytocin-neurophysin I precursor cDNA,” Co-Author, (1983) Nature 302, 342-344.
“Successful Use Of Inter Partes Review To Cancel Claims Asserted In Parallel Litigation,” Co-author, Duane Morris Blog, March 26, 2014.
“The USPTO Issues Its ‘Myriad’ Guidance – a.k.a. What Is Enough.” Co-author, Duane Morris Blog, March 4, 2014.
"Virginia Enacts The First State Law Regulating Interchangeable Biosimilar Products," Co-author, Duane Morris Alert, March 28, 2013.
"Path for Generics Open in Biotech," Co-author, The Recorder, March 5, 2012.
"FDA Issues Draft Guidance Documents to Implement the Biologics Price Competition and Innovation Act of 2009," Co-author, Duane Morris Alert, February 13, 2012.
"FDA's Draft Guidance on ‘Biosimilar’ Pathway Leaves Key Questions on Specific Clinical Data Requirements and Interchangeability Unanswered," Co-author, GenericsWeb newsletter InnSight, February 2012.
"FDA Sends Prescription Drug User Fee Act V to Congress for Reauthorization," Author, Duane Morris Alert, January 23, 2012.
"Forecasting Forthcoming 'Biosimilar' Drug Regulations," Co-author, The Recorder, August 30, 2011.
"A Look Ahead: FDA’s Approach to Biosimilars - Totality of the Evidence and Risk-Based," Author, GenericsWeb newsletter InnSight, August 2011.
"Biosimilars - Faster Development and Approval?" Author, GenericsWeb newsletter InnSight, March 2011.

References: v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v.